

Tiziana Crepaldi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8813705/tiziana-crepaldi-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

58

papers

6,082

citations

23

h-index

67

g-index

67

ext. papers

6,835

ext. citations

6.4

avg, IF

4.27

L-index

#	Paper	IF	Citations
58	Engineering, Characterization, and Biological Evaluation of an Antibody Targeting the HGF Receptor.. <i>Frontiers in Immunology</i> , 2021 , 12, 775151	8.4	0
57	Identification of novel circulating microRNAs in advanced heart failure by next-generation sequencing. <i>ESC Heart Failure</i> , 2021 , 8, 2907-2919	3.7	6
56	Factor XII protects neurons from apoptosis by epidermal and hepatocyte growth factor receptor-dependent mechanisms. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2235-2247	15.4	1
55	HGF and MET: From Brain Development to Neurological Disorders. <i>Frontiers in Cell and Developmental Biology</i> , 2021 , 9, 683609	5.7	9
54	Activation of the MET receptor attenuates doxorubicin-induced cardiotoxicity in vivo and in vitro. <i>British Journal of Pharmacology</i> , 2020 , 177, 3107-3122	8.6	11
53	Molecular Engineering Strategies Tailoring the Apoptotic Response to a MET Therapeutic Antibody. <i>Cancers</i> , 2020 , 12,	6.6	2
52	The Long-Lasting Protective Effect of HGF in Cardiomyoblasts Exposed to Doxorubicin Requires a Positive Feed-Forward Loop Mediated by Erk1,2-Timp1-Stat3. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	3
51	ERK: A Key Player in the Pathophysiology of Cardiac Hypertrophy. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	91
50	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016 , 12, 1-222	10.2	3838
49	Cardiac concentric hypertrophy promoted by activated Met receptor is mitigated in vivo by inhibition of Erk1,2 signalling with Pimasertib. <i>Journal of Molecular and Cellular Cardiology</i> , 2016 , 93, 84-97	5.8	6
48	Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes. <i>ELife</i> , 2016 , 5,	8.9	4
47	A New Transgenic Mouse Model of Heart Failure and Cardiac Cachexia Raised by Sustained Activation of Met Tyrosine Kinase in the Heart. <i>BioMed Research International</i> , 2016 , 2016, 9549036	3	7
46	Cellular and molecular mechanisms of HGF/Met in the cardiovascular system. <i>Clinical Science</i> , 2015 , 129, 1173-93	6.5	83
45	Anti-Differentiation Effect of Oncogenic Met Receptor in Terminally-Differentiated Myotubes. <i>Biomedicines</i> , 2015 , 3, 124-137	4.8	1
44	MicroRNAs in myocardial ischemia: identifying new targets and tools for treating heart disease. New frontiers for miR-medicine. <i>Cellular and Molecular Life Sciences</i> , 2014 , 71, 1439-52	10.3	30
43	HGF/Met Axis in Heart Function and Cardioprotection. <i>Biomedicines</i> , 2014 , 2, 247-262	4.8	21
42	Agonist antibodies activating the Met receptor protect cardiomyoblasts from cobalt chloride-induced apoptosis and autophagy. <i>Cell Death and Disease</i> , 2014 , 5, e1185	9.8	50

41	Gene expression profiling of HGF/Met activation in neonatal mouse heart. <i>Transgenic Research</i> , 2013 , 22, 579-93	3.3	12
40	Signaling to cardiac hypertrophy: insights from human and mouse RASopathies. <i>Molecular Medicine</i> , 2012 , 18, 938-47	6.2	32
39	Digoxin and ouabain induce the efflux of cholesterol via liver X receptor signalling and the synthesis of ATP in cardiomyocytes. <i>Biochemical Journal</i> , 2012 , 447, 301-11	3.8	24
38	A mouse model for spatial and temporal expression of HGF in the heart. <i>Transgenic Research</i> , 2011 , 20, 1203-16	3.3	8
37	Novel therapy for myocardial infarction: can HGF/Met be beneficial?. <i>Cellular and Molecular Life Sciences</i> , 2011 , 68, 1703-17	10.3	30
36	Activated Met signalling in the developing mouse heart leads to cardiac disease. <i>PLoS ONE</i> , 2011 , 6, e14675	14	
35	Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma. <i>European Journal of Cancer</i> , 2008 , 44, 876-84	7.5	23
34	Hepatocyte growth factor regulates migration of olfactory interneuron precursors in the rostral migratory stream through Met-Grb2 coupling. <i>Journal of Neuroscience</i> , 2008 , 28, 5901-9	6.6	55
33	An in vivo model of Met-driven lymphoma as a tool to explore the therapeutic potential of Met inhibitors. <i>Clinical Cancer Research</i> , 2008 , 14, 2220-6	12.9	15
32	The oncogenic transcription factor PAX3-FKHR can convert fibroblasts into contractile myotubes. <i>Experimental Cell Research</i> , 2007 , 313, 2308-17	4.2	15
31	Hepatocyte growth factor acts as a motogen and guidance signal for gonadotropin hormone-releasing hormone-1 neuronal migration. <i>Journal of Neuroscience</i> , 2007 , 27, 431-45	6.6	61
30	Ghrelin and des-acyl ghrelin promote differentiation and fusion of C2C12 skeletal muscle cells. <i>Molecular Biology of the Cell</i> , 2007 , 18, 986-94	3.5	163
29	Conditional activation of MET in differentiated skeletal muscle induces atrophy. <i>Journal of Biological Chemistry</i> , 2007 , 282, 6812-22	5.4	21
28	Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma. <i>Cancer Research</i> , 2006 , 66, 4742-9	10.1	132
27	RNAi technology and lentiviral delivery as a powerful tool to suppress Tpr-Met-mediated tumorigenesis. <i>Cancer Gene Therapy</i> , 2005 , 12, 456-63	5.4	31
26	Analysis of Mlc-lacZ Met mutants highlights the essential function of Met for migratory precursors of hypaxial muscles and reveals a role for Met in the development of hyoid arch-derived facial muscles. <i>Developmental Dynamics</i> , 2004 , 231, 582-91	2.9	36
25	Ligand-regulated binding of FAP68 to the hepatocyte growth factor receptor. <i>Journal of Biological Chemistry</i> , 2001 , 276, 46632-8	5.4	28
24	Effect of hepatocyte growth factor on assembly of zonula occludens-1 protein at the plasma membrane. <i>Journal of Cellular Physiology</i> , 1998 , 176, 465-71	7	40

23	Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. <i>Journal of Cell Biology</i> , 1997 , 138, 423-34	7.3	273
22	Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions*1. <i>Hepatology</i> , 1995 , 21, 1543-1546	11.2	4
21	Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions. <i>Hepatology</i> , 1995 , 21, 1543-1546	11.2	31
20	Targeting of the SF/HGF receptor to the basolateral domain of polarized epithelial cells. <i>Journal of Cell Biology</i> , 1994 , 125, 313-20	7.3	115
19	Overexpression of the Met/HGF receptor in ovarian cancer. <i>International Journal of Cancer</i> , 1994 , 58, 658-62	7.5	197
18	Quantitative expression of HLA class I molecules in acute non-lymphoblastic leukaemia cells. <i>International Journal of Immunogenetics</i> , 1993 , 20, 165-73		3
17	Chronic active hepatitis B. Interferon-activated natural killer-like cells against a hepatoma cell line transfected with the hepatitis B virus nucleic acid. <i>Liver</i> , 1991 , 11, 106-13		8
16	C-terminal truncated forms of Met, the hepatocyte growth factor receptor. <i>Molecular and Cellular Biology</i> , 1991 , 11, 5954-62	4.8	154
15	Activated human T cells express beta 2-microglobulin-associated HLA-A,B,C molecules not recognized by W6/32 mAb. <i>Tissue Antigens</i> , 1991 , 37, 138-40		4
14	The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. <i>International Journal of Cancer</i> , 1991 , 49, 323-8	7.5	269
13	IEF analysis of HLA molecules immunoprecipitated by putative anti-class I-like alloantisera. <i>International Journal of Immunogenetics</i> , 1990 , 17, 409-13		1
12	Expression of HLA class I antigens in human tumors and their involvement in tumor growth. <i>Research in Clinic and Laboratory</i> , 1990 , 20, 85-93		5
11	Expression of class I-like alloantigens on leukemic cells is not correlated with the amount of HLA-A,B,C molecules. <i>Tissue Antigens</i> , 1988 , 31, 270-3		
10	A new duplication at the C4B locus associated with the HLA-Aw68, Cw8, Bw65 haplotype. <i>International Journal of Immunogenetics</i> , 1988 , 15, 239-41		3
9	HLA class I-like antigen expression on human leukemic cells. <i>Tissue Antigens</i> , 1987 , 30, 76-83		4
8	New HLA class I-like alloantigens expressed on blast cells. <i>International Journal of Immunogenetics</i> , 1987 , 14, 219-29		6
7	Equine T lymphocytes express MHC class II antigens. <i>International Journal of Immunogenetics</i> , 1986 , 13, 349-60		54
6	Further antigenic determinants on HLA-A molecules. <i>Tissue Antigens</i> , 1985 , 25, 69-74		2

- 5 The monoclonal antibody AC1.59 defines a new polymorphic determinant on HLA-DR molecules. *Tissue Antigens*, **1985**, 26, 25-34 11
- 4 New HLA antigenic determinant shared by A2 and a subtype of Bw16 molecules detected by a monoclonal antibody. *Human Immunology*, **1983**, 7, 17-23 2,3 9
- 3 Characterization by monoclonal antibodies of lymphocyte subsets present in B-enriched suspensions. *Tissue Antigens*, **1982**, 20, 282-8 2
- 2 Cytolytic activity of monoclonal antibodies strongly depends on rabbit complement used. *Tissue Antigens*, **1981**, 17, 368-71 7
- 1 A xenogeneic monoclonal antibody recognizing specificities controlled by HLA-A and B alleles. *Immunogenetics*, **1981**, 12, 615-26 3,2 14